A cost–utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada
Abstract
Aim: The prevalence of Type 2 diabetes in Canada is estimated to be 7.6% and rising. Given the substantial economic burden associated with Type 2 diabetes treatment, optimizing healthcare expenditure is extremely important. In the present analysis, we evaluated the cost–effectiveness of dulaglutide 1.5 mg, a once-weekly glucagon-like peptide 1 agonist as third-line therapy relative to insulin glargine from the perspective of a Canadian healthcare payer. Methods: A patient-level cost-utility model of Type 2 diabetes was developed to capture seven microvascular and macrovascular complications and severe and nonsevere hypoglycemia. Cohort characteristics and the relative efficacy of dulaglutide 1.5 mg and insulin glargine were derived from the AWARD-2 head-to-head trial, which was identified by systematic literature review. Cost data were derived from Canadian sources and expressed in 2016 Canadian dollars (CAD), and future cost and quality-adjusted life expectancy (QALE) estimates were discounted at 1.5% per annum. One-way and probabilistic sensitivity analyses were conducted. Results: Based on the AWARD-2 trial, relative to insulin glargine, dulaglutide 1.5 mg was projected to increase QALE by 0.38 quality-adjusted life years and increase costs by CAD 19,773, resulting in an incremental cost–effectiveness ratio of CAD 52,580 per quality-adjusted life year gained. Conclusion: A computer simulation analysis showed that dulaglutide 1.5 mg would likely be cost-effective relative to insulin glargine in patients with Type 2 diabetes inadequately controlled on metformin and sulfonylurea in Canada.
Supplementary Material
File (suppl_file.docx)
- Download
- 508.11 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
International Diabetes Federation. IDF Diabetes Atlas (8th Edition). International Diabetes Federation, Brussels, Belgium (2017). www.idf.org/diabetesatlas.
2.
Greiver M, Williamson T, Barber D et al. Prevalence and epidemiology of diabetes in Canadian primary care practices: a report from the Canadian Primary Care Sentinel Surveillance Network. Can. J. Diabetes 38, 179–185 (2014).
3.
Canadian Diabetes Association. Access, equity and prosperity for all. Recommendations by the Canadian Diabetes Association for the 2011 Federal Budget (2010). www.diabetes.ca/CDA/media/documents/about/cda-recommendations-for-2011-federal-budget-english.pdf.
4.
Goeree R, Lim ME, Hopkins R et al. Prevalence, total and excess costs of diabetes and related complications in Ontario, Canada. Can. J. Diabetes 33, 35–45 (2009).
5.
Nathan DM. Long-term complications of diabetes mellitus. N. Engl. J. Med. 328, 1676–1685 (1993).
6.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the prevention and management of diabetes in Canada. Can. J. Diabetes 37(Suppl. 1), S1–S212 (2013).
7.
Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in Type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58(3), 429–442 (2015).
8.
Canadian Agency for Drugs and Technologies in Health. Second-line pharmacotherapy for Type 2 diabetes – update. CADTH Optimal Use Report 3(1A), (2013). www.cadth.ca/media/pdf/OP0512_DiabetesUpdate_Second-line_e.pdf.
9.
Canadian Agency for Drugs and Technologies in Health. Third-line pharmacotherapy for Type 2 diabetes – update. CADTH optimal use report 3(1B), (2013). www.cadth.ca/sites/default/files/pdf/OP0512_Diabetes%20Update_Third-line_e.pdf.
10.
Clarke PM, Gray AM, Briggs A et al. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS No. 68). Diabetologia 47(10), 1747–1759 (2004).
•• Includes all of the parameters for the United Kingdom Prospective Diabetes Study Outcomes Model risk equations that governed the long-term projections of diabetes complication risk.
11.
Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safety of dulaglutide in the treatment of Type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD Phase III clinical trial program. Diabetes Metab. Res. Rev. 32(8), 776–790 (2016).
12.
Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with Type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 38(12), 2241–2249 (2015).
•• The findings of the AWARD-2 randomized controlled trial informed the changes in key risk factors with dulaglutide 1.5 mg relative to insulin glargine.
13.
Express Scripts Canada. Express scripts Canada® drug trend report 2016 (2017). www.express-scripts.ca/sites/default/files/2016-Drug-Trend-Report.pdf.
14.
Statistics Canada Demography Division. Life tables, canada, provinces and territories, 2009 to 2011. www.statcan.gc.ca/pub/84-537-x/84-537-x2013005-eng.pdf.
15.
Harris SB, Ekoe JM, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res. Clin. Pract. 70(1), 90–7 (2005).
16.
Hux JE, Booth GL, Slaughter PM, Laupacis A. Diabetes in Ontario: an ICES practice atlas. Toronto, Canada (2003). www.ices.on.ca/∼/media/Files/Atlases-Reports/2003/Diabetes-in-Ontario/Full%20report.ashx.
17.
Institute of Health Economics. Alberta Diabetes Atlas 2007. Edmonton, Canada (2007). www.ihe.ca/advanced-search/alberta-diabetes-atlas-2007.
18.
Canadian Agency for Drugs and Technologies in Health. CADTH therapeutic review. Economic evaluation: third-line therapy for patients with Type 2 diabetes inadequately controlled with metformin and sulfonylurea combination therapy (2010). www.cadth.ca/sites/default/files/pdf/Diabetes_TR_Economic_Evaluation_Final_e.pdf.
•• A previous economic evaluation of third-line therapies for Type 2 diabetes conducted by the Canadian Agency for Drugs and Technologies in Health (CADTH) was used to tailor multiple aspects of the analysis to the Canadian reimbursement environment.
19.
Holman RR, Farmer AJ, Davies MJ et al. Three-year efficacy of complex insulin regimens in Type 2 diabetes. N. Engl. J. Med. 361(18), 1736–1747 (2009).
• The findings of the Treating To Target in Type 2 Diabetes (4-T) randomized controlled trial were used to inform changes in risk factors occurring at the time of treatment intensification to basal-bolus insulin.
20.
Ontario Ministry of Health and Long-Term Care. Ontario drug benefit formulary/comparative drug index formulary search. www.formulary.health.gov.on.ca/formulary/.
21.
Gomes T, Juurlink DN, Shah BR, Paterson JM, Mamdani MM. Blood glucose test strips: options to reduce usage. CMAJ 182(1), 35–38 (2010).
22.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Clinical practice guidelines. Can. J. Diabetes 37, S1–S212 (2013). http://guidelines.diabetes.ca/app_themes/cdacpg/resources/cpg_2013_full_en.pdf.
23.
Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med. Decis. Making 26(4), 410–420 (2006).
24.
Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med. Care 43(7), 736–749 (2005).
25.
Clarke P, Gray A, Holman R. Estimating utility values for health states of Type 2 diabetic patients using the EQ-5D (UKPDS 62). Med. Decis. Making 22(4), 340–349 (2002).
26.
Harris S, Mamdani M, Galbo-Jørgensen CB, Bøgelund M, Gundgaard J, Groleau D. The effect of hypoglycemia on health-related quality of life: Canadian results from a multinational time trade-off survey. Can. J. Diabetes 38(1), 45–52 (2014).
27.
Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 14(3), 217–230 (2005).
28.
Jönsson B, CODE-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia 45(7), S5–S12 (2002).
29.
Scottish Medicines Consortium. Advice on Tresiba. www.scottishmedicines.org.uk/files/advice/insulin_degludec_Tresiba_FINAL_March_2013_for_website.pdf.
30.
Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada (4th Edition). CADTH, Ottawa, Canada (2017). www.cadth.ca/sites/default/files/pdf/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf.
• The analysis was conducted in line with the latest (2018) economic evaluation guidelines from the Canadian Agency for Drugs and Technologies in Health.
31.
Levy AR, Christensen TL, Johnson JA. Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health Qual. Life Outcomes 6, 73 (2008).
32.
United Kingdom Prospective Diabetes Study (UKPDS) Group. UKPDS VIII. Study design, progress and performance. Diabetologia 34(12), 877–890 (1991).
Information & Authors
Information
Published In
Copyright
© 2019 Eli Lilly and Company.
History
Received: 19 July 2018
Accepted: 3 December 2018
Published online: 15 January 2019
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
A cost–utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada. (2019) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2018-0073
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Mari Pesonen, Virpi Jylhä, Eila Kankaanpää, Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review, JBI Evidence Synthesis, 10.11124/JBIES-23-00511, 22, 11, (2194-2266), (2024).
- Suman Baishnab, Ravinder Singh Jaura, Saksham Sharma, Honey Garg, Thakur Gurjeet Singh, Pharmacoeconomic Aspects of Diabetes Mellitus: Outcomes and Analysis of Health Benefits Approach, Current Diabetes Reviews, 10.2174/0115733998246567230924134603, 20, 8, (2024).
- Meredith Hoog, Juan M. Maldonado, Ruth Wangia-Dixon, Rachel Halpern, Erin Buysman, Garrett W. Gremel, Ahong Huang, Manige Konig, Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study, Diabetes Therapy, 10.1007/s13300-024-01542-5, 15, 4, (855-867), (2024).
- Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Andrej Belančić, Jacques Bazile, Emma Marland, Dinko Vitezić, A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes, Diabetology, 10.3390/diabetology4040038, 4, 4, (440-452), (2023).
- Chun-Ting Yang, Wen-Yu Yao, Huang-Tz Ou, Shihchen Kuo, Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data, Diabetes Research and Clinical Practice, 10.1016/j.diabres.2023.110625, 198, (110625), (2023).
- Irene Romera, Miriam Rubio-de Santos, Sara Artola, Carmen Suárez Fernández, Ignacio Conget, GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice, Advances in Therapy, 10.1007/s12325-023-02442-z, 40, 4, (1418-1429), (2023).
- Lizheng Shi, Vivian Fonseca, Belinda Childs, Economic burden of diabetes-related hypoglycemia on patients, payors, and employers, Journal of Diabetes and its Complications, 10.1016/j.jdiacomp.2021.107916, 35, 6, (107916), (2021).
- Chen-Yi Yang, Ying-Ren Chen, Huang-Tz Ou, Shihchen Kuo, Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review, Cardiovascular Diabetology, 10.1186/s12933-020-01211-4, 20, 1, (2021).
- Enrico Torre, Giacomo M Bruno, Sergio Di Matteo, Chiara Martinotti, Maria Chiara Valentino, Luigi C Bottaro, Giorgio L Colombo,
Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study
, ClinicoEconomics and Outcomes Research, 10.2147/CEOR.S240183, Volume 12, (177-189), (2020). - Dulaglutide cost effective as third-line therapy in T2DM in Canada, PharmacoEconomics & Outcomes News, 10.1007/s40274-019-5592-4, 820, 1, (13-13), (2019).